Abstract
GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 905-910 |
| Number of pages | 6 |
| Journal | International Journal of Oncology |
| Volume | 6 |
| Issue number | 4 |
| State | Published - Jan 1 1995 |
| Externally published | Yes |
Fingerprint
Keywords
- Gonadotropin-releasing hormone (GnRH)
- Ovarian cancer
- Vascular endothelial growth factor (VEGF)
- Vascular permeability factor (VPF)
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist. / Olson, T. A.; Mohanraj, D.; Ramakrishnan, Sundaram.
In: International Journal of Oncology, Vol. 6, No. 4, 01.01.1995, p. 905-910.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist
AU - Olson, T. A.
AU - Mohanraj, D.
AU - Ramakrishnan, Sundaram
PY - 1995/1/1
Y1 - 1995/1/1
N2 - GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.
AB - GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.
KW - Gonadotropin-releasing hormone (GnRH)
KW - Ovarian cancer
KW - Vascular endothelial growth factor (VEGF)
KW - Vascular permeability factor (VPF)
UR - http://www.scopus.com/inward/record.url?scp=0028959339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028959339&partnerID=8YFLogxK
M3 - Article
VL - 6
SP - 905
EP - 910
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 4
ER -